CRISPR Therapeutics (CRSP) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Pipeline overview and innovation

• Achieved first global approval for a CRISPR-based medicine, CASGEVY, targeting sickle cell and thalassemia, now in commercial launch with broad pipeline expansion into ex vivo and in vivo therapies.

• Ex vivo programs include allogeneic CAR T therapies (CTX112) for oncology and autoimmune diseases; in vivo programs target liver editing for LP(a) and ANGPTL3, with regenerative medicine efforts in type 1 diabetes and solid tumors.

CASGEVY launch and commercialization

• Commercial launch led by Vertex, with exponential growth in patient cell collections and increasing activation of authorized treatment centers (ATCs).

• Market opportunity is larger than anticipated in regions like France and the UK, with ongoing efforts to expand patient access through gentler conditioning regimens.

• Targeted conditioning agents are being developed in parallel with Vertex, aiming to triple the addressable market if successful.

• Profit-sharing agreement remains unchanged regardless of which partner's conditioning program is adopted.

• Long-term vision includes in vivo bone marrow editing, potentially shifting to a 50/50 profit-sharing structure in 8–10 years.

Allogeneic CAR T (CTX112) and oncology/autoimmune pipeline

• CTX112 shows promising efficacy and safety, with high complete response rates and potential to outperform autologous CAR T therapies, especially as it moves into community settings.

• Safety profile is favorable, with manageable CRS and lower rates of severe ICANS compared to autologous CAR T, supporting broader adoption.

• No theoretical limit to the number of gene edits in CAR T products, with current technology enabling up to 8–9 edits per cell.

• Allogeneic CAR T therapies are positioned as more potent and practical than T cell engagers or autologous therapies in autoimmune diseases, with the ability to redose and achieve durable remissions in 70–80% of patients.

• Multiple data readouts expected in the next 6–12 months for oncology, autoimmune, in vivo, and solid tumor programs.